Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

Also called NCT07175428

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 1,200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07175428
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07175428. Randomized; single masking; primary purpose prevention. Start 2025-10-20 (actual); primary completion 2027-02-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Acronym
ROXI-ATLAS
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
REGN7508
Intervention (Drug)
REGN9933
Intervention (Drug)
Apixaban
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07175428
Content hash
682c2935bf6677f4635d546d4449987b447107b1ae6e0bc0881e030fcb78c66b